Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5085422
Max Phase: Preclinical
Molecular Formula: C48H57N7O6S2
Molecular Weight: 892.16
Molecule Type: Unknown
Associated Items:
ID: ALA5085422
Max Phase: Preclinical
Molecular Formula: C48H57N7O6S2
Molecular Weight: 892.16
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)CCCCCCCC(=O)Nc2ccc(C(=O)Nc3cc(-c4cccs4)ccc3N)cc2)C(C)(C)C)cc1
Standard InChI: InChI=1S/C48H57N7O6S2/c1-30-43(63-29-51-30)32-16-14-31(15-17-32)27-50-46(60)39-26-36(56)28-55(39)47(61)44(48(2,3)4)54-42(58)13-9-7-5-6-8-12-41(57)52-35-21-18-33(19-22-35)45(59)53-38-25-34(20-23-37(38)49)40-11-10-24-62-40/h10-11,14-25,29,36,39,44,56H,5-9,12-13,26-28,49H2,1-4H3,(H,50,60)(H,52,57)(H,53,59)(H,54,58)/t36-,39+,44-/m1/s1
Standard InChI Key: SLSLECNMOKDWNA-INMVVMDYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 892.16 | Molecular Weight (Monoisotopic): 891.3812 | AlogP: 8.16 | #Rotatable Bonds: 18 |
Polar Surface Area: 195.85 | Molecular Species: NEUTRAL | HBA: 10 | HBD: 6 |
#RO5 Violations: 3 | HBA (Lipinski): 13 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 4 |
CX Acidic pKa: 12.56 | CX Basic pKa: 2.93 | CX LogP: 5.84 | CX LogD: 5.84 |
Aromatic Rings: 5 | Heavy Atoms: 63 | QED Weighted: 0.04 | Np Likeness Score: -0.86 |
1. Smalley JP, Baker IM, Pytel WA, Lin LY, Bowman KJ, Schwabe JWR, Cowley SM, Hodgkinson JT.. (2022) Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells., 65 (7.0): [PMID:35293758] [10.1021/acs.jmedchem.1c02179] |
Source(1):